10 completed, 2 enrolling by invitation, 2 recruiting, 1 terminated. 5 Phase 1, 5 Phase 4, 2 Phase 2, 2 Phase 3, 1 Not applicable.
Follow Cefadroxil: new trials by email Literature Review of Cefadroxil trials Research Report on Cefadroxil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extended Oral Antibiotic Prophylaxis in Diabetic Fracture Patients Cefadroxil 500 mg Capsules, Clindamycin, Bactrim DS - Fracture Lower Leg, Diabetes | Phase 4 | Recruiting | Texas Tech University Health Sciences Center, El Paso | 40 | 2026-04-01 | 2026-05-08 |
| Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing, Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge, Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge - Drug Allergy, Cephalosporin Allergy | Phase 2 | Recruiting | Massachusetts General Hospital | 300 | 2025-05-05 | 2026-09-04 |
| Comparing Oral Versus Parenteral Antimicrobial Therapy Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem - Endovascular Infection, Bone and Joint Infection | Phase 4 | Terminated | West Virginia University | 94 | 2023-08-04 | 2025-08-26 |
| Or v IV Antibiotics for Infection Bactrim, Cefadroxil, Doxycycline Hcl - Joint Infection | Phase 3 | Enrolling by invitation | Rothman Institute Orthopaedics | 308 | 2021-01-25 | 2026-10-08 |
| Antibiotic Prophylaxis in High-Risk Arthroplasty Patients Cephalexin, Doxycycline, Cefadroxil - Infections Joint Prosthetic, Overweight or Obesity | Phase 4 | Enrolling by invitation | Mayo Clinic | 4618 | 2020-06-11 | 2026-07-06 |
| Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections Cefadroxil, Cephalexin - Osteomyelitis, Septic Arthritis | Phase 1 | Completed | University of Colorado, Denver | 17 | 2019-05-01 | 2021-06-02 |
| Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers Faropenem, Amoxicillin/clavulanic acid, Cefadroxil - Pulmonary Tuberculosis | Phase 2 | Completed | National University Hospital, Singapore | 58 | 2019-02-11 | 2020-03-23 |
| Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA Dalbavancin, Vancomycin, Oxacillin - Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections | Phase 3 | Completed | AbbVie | 199 | 2017-03-30 | 2024-09-19 |
| To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers Treatment A (cefadroxil alone), Treatment B - AZD1722 followed by cefadroxil - Healthy Volunteers | Phase 1 | Completed | Ardelyx | 71 | 2014-05-01 | 2015-09-22 |
| A Bioequivalence Study of Cefadroxil Film Coated Tablets After A Single Oral Dose Administration to Healthy Subjects Cefadroxil tablets manufactured by GSK, Cefadroxil tablets manufactured by NP - Infections, Urinary Tract | Phase 4 | Completed | GlaxoSmithKline | 24 | 2014-03-31 | 2017-09-21 |
| A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma) Cefadroxil - Healthy | Phase 1 | Completed | Genuine Research Center, Egypt | 24 | 2014-03-01 | 2015-06-24 |
| Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction Cefadroxil discontinued early, Cefadroxil until drain removal - Bacterial Infection, Anti-infective Agents | Phase 4 | Completed | Stony Brook University | 132 | 2010-11-01 | 2014-05-13 |
| Cefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects. Cefadroxil 500 mg Capsules, DURICEF® capsules 500 mg - Healthy | Phase 1 | Completed | Teva Pharmaceuticals USA | 26 | 2004-09-01 | 2024-08-19 |
| Cefadroxil 500 mg Capsules Under Fasting Conditions Cefadroxil 500 mg Capsules, DURICEF® capsules 500 mg - Healthy | Phase 1 | Completed | Teva Pharmaceuticals USA | 26 | 2004-09-01 | 2024-08-19 |
| Study of Acupuncture and Care Interventions for the Treatment of Breast Inflammation During Breastfeeding Acupuncture treatment, Administration of oxytocin nasal spray, Improved breast milk removal - Mastitis | Not applicable | Completed | Karlstad University | 210 | 2002-01-01 | 2006-12-04 |
Bacterial Infections (2) · Diabetes Mellitus (2) · Anaphylaxis (1) · Arthritis, Infectious (1) · Autoimmune Diseases (1) · Breast Feeding (1) · Drug Hypersensitivity (1) · Hypersensitivity (1) · Mastitis (1) · Obesity (1) · Osteomyelitis (1) · Overweight (1) · Pyomyositis (1) · Renal Insufficiency, Chronic (1) · Soft Tissue Infections (1)
Teva Pharmaceuticals USA (2) · AbbVie (1) · Ardelyx (1) · Genuine Research Center, Egypt (1) · GlaxoSmithKline (1) · Karlstad University (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · National University Hospital, Singapore (1) · Rothman Institute Orthopaedics (1) · Stony Brook University (1) · Texas Tech University Health Sciences Center, El Paso (1) · University of Colorado, Denver (1) · West Virginia University (1)
United States (11) · Canada (2) · Egypt (2) · Argentina (1) · Belarus (1) · Brazil (1) · Bulgaria (1) · Chile (1) · Colombia (1) · Georgia (1) · Greece (1) · Guatemala (1) · Latvia (1) · Lithuania (1) · Mexico (1)
Paul Y Tam, M.D. (2) · Ahmed Elshafeey, Ph.D.Pharma (1) · Andrew Haynes, MD (1) · Arif R. Sarwari, MD, MSc, MBA (1) · Bodil Wilde Larsson, PhD (1) · Brett T Phillips, MD (1) · David A Khan, MD (1) · Duc T Bui, MD (1) · Joy J. Juskowich, MD (1) · Kimberly G Blumenthal, MD, MSc (1) · Linda J Kvist, PhD (1) · Nicholas Bedard, MD (1)
2014 (1), U01AI184071 (1)